Explore >> Select a destination
|
You are here 
|
diabetesjournals.org | ||
| | | | |
www.jci.org
|
|
| | | | | [AI summary] The provided text is a compilation of numerous scientific articles and studies, primarily focused on obesity, diabetes, and related metabolic disorders. The research spans a wide range of topics, including the role of gut hormones like GLP-1 and PYY in regulating food intake and glucose metabolism, the mechanisms of action of various drugs and peptides, and their therapeutic applications in managing metabolic diseases. Key areas of focus include the use of GLP-1 receptor agonists for weight loss and glycemic control, the potential of dual agonists targeting multiple receptors, and the exploration of endocrine signals such as GDF15 in nutritional stress. Additionally, the text touches on the physiological and pharmacological aspects of these inte... | |
| | | | |
www.adventhealth.com
|
|
| | | | | With obesity a major health concern, impacting more than 40% of American adults, | |
| | | | |
www.horsejournals.com
|
|
| | | | | Our knowledge of optimal equine management is continually expanding. The science relied upon to make informed management decisions for our horses is changing as more research becomes available. One of the primary nutrition concerns across North America is the management of horses with metabolic health issues. This article will discuss the goals of nutritional management for these horses, how science has evolved, and updated guidelines based on the newest science for horse owners to follow. | |
| | | | |
www.detroitnews.com
|
|
| | | Novo Nordisk A/S's blockbuster diabetes drug Ozempic cut patients' risk of dying in a kidney-disease study, the latest research pointing to the medicine's usefulness in a constellation of disorders. | ||
